Tcr2 Therapeutics Inc (TCRR) Stock
TCRR is no longer traded. Tcr2 Therapeutics was delisted from the Nasdaq in May 2023.
Prices on this page are historical; the last trade was May 31, 2023 at $1.48.
Tcr2 Therapeutics stock price history
TCRR final trading statistics
- Final close
- $1.48
- Final trading day
- May 31, 2023
- Market cap at delisting
- $58.11M
- Shares outstanding
- 39.26M
- Final 52-week range
- $0.82 – $3.88
- Avg. volume (final 3 mo.)
- 701,399
- All-time high (split-adj.)
- $34.07 · Jan 2021
- All-time low (split-adj.)
- $0.83 · Dec 2022
- Return since IPO
- -90.2%
- Beta
- 1.93
- Book value / share
- $2.58
- Price / book
- 0.57
Tcr2 Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$151.8M | -$3.93 |
| FY2021 | $0.00 | -$99.8M | -$2.63 |
| FY2020 | $0.00 | -$67.1M | -$2.43 |
| FY2019 | $0.00 | -$47.6M | -$6.43 |
| FY2018 | $0.00 | -$24.3M | -$16.22 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Tcr2 Therapeutics Inc
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Tcr2 Therapeutics stock FAQ
What happened to Tcr2 Therapeutics stock?
Tcr2 Therapeutics stock was delisted from the Nasdaq. Its final close was $1.48 on May 31, 2023.
Is TCRR stock still trading?
No. TCRR was delisted from the Nasdaq in May 2023 and no longer trades on a U.S. exchange.
What was the last price of TCRR stock?
TCRR closed at $1.48 on its final trading day, May 31, 2023, for a market value of about $58.11M.
What were Tcr2 Therapeutics's revenue and earnings in its last full fiscal year?
Tcr2 Therapeutics reported revenue of $0.00 and net income of -$151.8M in fiscal 2022, its last full year as a public company.
When did Tcr2 Therapeutics go public?
Tcr2 Therapeutics Inc stock began trading on February 14, 2019.